Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech
Mandate

Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech

October 29, 2018 Capital Markets and Public M&A

Galecto Biotech AB, the developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, has closed a €79 million financing co-led by Ysios Capital and OrbiMed.

New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round.
 
Vinge advised the new investors. The Vinge team included Jesper Ottergren, Erik Sjöman and Charlotte Akej.
 

Related

Vinge has advised Gamma Waves on Sportway’s EUR 20 million financing round

 Vinge has acted as legal adviser to Gamma Waves in connection with Sportway’s EUR 20 million financing round. The round was led by Gamma Waves, together with continued participation from existing shareholders, and values Sportway at approximately EUR 92 million (around SEK 1 billion) post-money.
June 24, 2026

Vinge advises Spotlight Group in connection with offer from Kriptown

 Vinge is advising Spotlight Group AB (publ) in connection with Kriptown SAS having made a public cash takeover offer to the shareholders of Spotlight Group
June 17, 2026

Vinge has advised EQT IX in connection with its exit of Beijer Ref AB (publ)

 Vinge has advised EQT IX (”EQT”) in connection with the sale of all of its remaining shares of series B in Beijer Ref AB (publ) through an accelerated bookbuilding process carried out on 15 June 2026.
June 16, 2026